Investors caught a break in what was a mildly positive Tuesday session for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares.

After starting strong this morning, the ASX 200 took a brief dip into negative territory in afternoon trading. But investors’ feet warmed back up by the time the markets closed, with the index lifting 0.36% to 8,614.3 points.

This happier trading session came after a bullish start to the American trading week in the early hours of this morning.

The Dow Jones Industrial Average Index (DJX: .DJI) rose by an optimistic 0.83%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) fared even better, gaining a solid 1.22%.

But let’s return to the ASX now and take stock of how the various ASX sectors enjoyed (or not) today’s renewed sense of optimism.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• What are the 5 emerging ASX gold companies UBS has picked as winners?
• ASX 200 resilient in face of latest RBA interest rate increase
• Why Challenger, Meeka Metals, Vulcan Energy, and West African Resources shares are rising today
• Worst fortnight in 4 years: How the Iran war is affecting ASX shares
• Morgans names 3 ASX mining stocks to buy

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Bell Potter has been running the rule over a number of small-cap ASX healthcare stocks this week.

Let’s see what the broker is saying about these speculative stocks.

Immutep Ltd (ASX: IMM)

Immutep is a clinical-stage biopharmaceutical company focused on developing novel LAG3 immunotherapy for cancer and autoimmune disease.

Its shares were sold off this month after its lead drug, Efti, failed the futility analysis in its global Phase 3 trial in non-small cell lung cancer. Bell Potter notes that this “is a bitterly disappointing and surprising outcome considering the strength of the company’s prior Phase 1 and Phase 2 lung cancer data.”

As a result, it has downgraded its shares to a speculative hold rating with a 7 cents price target (from 65 cents). It said:

We downgrade to a Hold recommendation and $0.07 valuation. We tentatively estimate IMM will end up with ~$60m of cash (4c/sh) following wind-down of the global Phase 3 trial and other Efti development activities, assuming no repayments to Dr Reddy’s are necessary.

In addition to cash, IMM retains the earlier-stage IMP761 asset which it will continue to progress for treating autoimmune conditions. The early stage of IMP761’s development (no data in patients) leads us to exclude any material contribution from our valuation at this time.

Oneview Healthcare PLC (ASX: ONE)

Another ASX healthcare stock that Bell Potter has been looking at is Oneview.

Its Care Experience Platform (CXP) is a unified set of digital tools in a single bedside solution that connects patients, families, and care teams with services, education, and information during hospital stays.

Bell Potter is positive on the company’s growth outlook and has put a speculative buy rating and 45 cents price target on its shares. It said:

There is no change to our earnings estimates but we have reduced our DCF valuation by c.10% to $0.45/sh following FX appreciation and share count adjustments. We assume c.20% annual growth in live endpoints from FY26e-FY28e to drive our FY28e U. EBITDA breakeven expectation.

Given ONE’s track record, this is no small feat. In the face of improving thematics and the need for hospitals to utilise efficiency tools to plug the operating impact of nurse shortages, we remain cautious ahead of more consistent performance on conversion and financial performance.

PYC Therapeutics Ltd (ASX: PYC)

Finally, PYC is a clinical-stage biotechnology company that is developing multiple drug candidates for rare inherited diseases.

Bell Potter notes that “following a Type D meeting with the FDA, PYC provided key elements of the Phase 3 trial design for its novel drug candidate, VP-001.”

And thanks to its recent $600 million capital raise, PYC has the benefit of >$700 million in cash, with runway into at least 2030 according to the broker. As a result, Bell Potter believes the company is “incredibly well capitalised to execute over the next several years on its clinical development programs without having to come back to investors for additional capital.”

For this reason, it has put a speculative buy rating and $2.30 price target on its shares. It said:

There are no changes to our BUY (spec.) recommendation or $2.30/sh valuation. The catalysts most likely to drive enthusiasm include additional RP11 readouts from the Phase 1/2 trial (expected Q4 CY26), clinical data in patients in the PKD trial (CY27 to CY28), and any potential licensing partnerships for the ophthalmology programs.

The post How does Bell Potter rate these ASX healthcare stocks appeared first on The Motley Fool Australia.

More reading

• Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today
• Game over? ASX biotech stock crashes 90% on big bad news
• Why the Immutep share price is halted today
• The cutting edge ASX healthcare stock that could rise 50%

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Nvidia Corp (NASDAQ: NVDA) moved higher overnight after the chip giant’s Chief Executive delivered a major update on the company’s artificial intelligence outlook.

At the close of trade, the Nvidia share price finished 1.65% higher at US$183.22.

The gain came after CEO Jensen Huang outlined the scale of the opportunity ahead for the company’s AI processors.

Here’s the latest information.

Nvidia CEO outlines huge AI revenue opportunity

Speaking at the company’s GTC developer conference in San Jose, Huang said Nvidia now sees at “least US$1 trillion” in potential revenue tied to its latest generation of AI chips.

The projection relates primarily to Nvidia’s new Blackwell and Rubin chip architectures. These are designed for large-scale AI computing and data centre workloads.

According to the presentation, the chips are expected to power the next wave of AI infrastructure. This comes as major technology companies continue investing heavily in data centres and advanced computing systems.

The forecast effectively doubles the US$500 billion opportunity the company previously outlined late last year.

Huang told attendees the scale of demand from hyperscale cloud providers and enterprise customers continues to grow rapidly as AI applications expand.

New AI systems and infrastructure revealed

During the event, Nvidia also introduced new computer systems designed to run AI faster.

One of the key announcements was a new server platform that combines 72 of Nvidia’s next generation Vera Rubin chips with advanced networking and memory technology.

The systems are designed to handle large AI workloads much faster than earlier hardware.

Nvidia said the platform can produce hundreds of millions of AI tokens per second, which means AI models can generate responses more quickly.

These upgrades are designed to support the growing demand for AI inference, which is when trained AI models are used in real-world applications. This includes chatbots, search tools, and other software.

Nvidia remains central to the AI boom

Nvidia has become one of the most important companies in the global AI supply chain.

Its graphics processing units (GPUs) are widely used by technology companies building and operating large language models and other AI tools.

Demand for these chips has surged over the past 2 years as businesses accelerate spending on AI infrastructure.

The company’s most recent quarterly results highlighted the scale of that growth. Nvidia reported revenue of US$68.1 billion for the quarter, representing 73% year-on-year growth.

That rapid expansion has cemented Nvidia’s position as a critical supplier to the world’s largest tech companies.

The post Nvidia CEO reveals massive US$1 trillion AI chip opportunity appeared first on The Motley Fool Australia.

More reading

• Just 3 ASX ETFs could build a lazy Australian millionaire portfolio
• Have ASX technology shares finally hit rock bottom?
• Is NextDC the ASX share closest to Nvidia?
• 3 ASX ETFs for a stress-free start to investing
• Why Nvidia’s insights suggest ASX tech shares are undervalued

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Nvidia. The Motley Fool Australia has recommended Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Electro Optic Systems Holdings Ltd (ASX: EOS) shares are having a day to forget on Tuesday.

After trading largely flat for most of the session, the ASX defence stock is now down 25% to $8.00 in late trade.

Why are EOS shares crashing today?

The company’s shares are crashing following the release of an announcement detailing significant insider selling after the exercise of options.

According to the release, EOS’ CEO and managing director, Dr Andreas Schwer, the CFO/COO Clive Cuthell, and other members of the management team have exercised a total of 3,429,299 options to acquire 3,299,599 EOS shares.

These options were granted under the company’s long-term incentive plan after performance and service hurdles were met during the 2024 and 2025 financial years.

Management was able to exercise the majority of these options for just 50 cents each.

Planned share sales

However, rather than hold onto these shares, senior executives intend to sell a large portion of them.

The release notes that its CEO, Dr Schwer, has been approved to dispose of up to 2,500,000 shares in the near term, with the final number to be determined within that limit.

Based on yesterday’s close price of $10.72, these shares had a market value of $26.8 million.

The company notes that this planned disposal is intended to allow him to fund personal expenses, including the construction of a family home and a divorce settlement.

In addition, the CFO/COO and other members of the management team have indicated that they also intend to dispose of some or all of their shareholdings in the near term.

Minimum holdings still met

Despite the planned disposals, the company expects that both Dr Schwer and Mr Cuthell will retain shareholdings well above the minimum levels required under its recently announced shareholding policy.

This is a minimum of four times the CEO’s fixed annual remuneration and three times the CFO/COO’s fixed annual remuneration.

Nevertheless, investors appear to be reacting negatively to the scale of the potential insider selling.

After all, insider selling is often seen as a bearish indicator, as few insiders would be happy to part with their shares if they felt that they were about to increase in value.

The post Why are EOS shares crashing 25% today? appeared first on The Motley Fool Australia.

More reading

• Up 80% over the last month, EOS shares are near all-time highs. Should investors buy, hold or sell?
• Why Cobram Estate, EOS, Magellan, and Rio Tinto shares are storming higher today
• Electro Optic Systems shares jump on new Middle East contract win
• Why EOS, GQG, Liontown, and Temple & Webster shares are tumbling today
• Why are EOS shares crashing 10% today?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If I had $10,000 ready to invest in Australian shares right now, I would be looking for companies with strong global businesses.

Ideally, they would also be businesses that have recently fallen out of favour with the market.

Short term share price weakness can sometimes create opportunities to buy high-quality companies at far more attractive prices.

Right now, two ASX stocks stand out to me as particularly interesting opportunities.

Here’s why.

WiseTech Global Ltd (ASX: WTC)

The WiseTech share price is currently down 1.72% to $45.83.

That means the logistics software company has fallen more than 45% over the past year and about 33% since the start of 2026.

Despite this sharp decline, the underlying business remains one of the most dominant technology platforms in global logistics.

WiseTech is best known for its CargoWise platform, which helps freight forwarders and logistics providers manage complex global supply chains.

Once customers adopt the software, switching away can be extremely difficult. This creates strong recurring revenue and high margins.

The company recently reported revenue of US$672 million in the first-half of FY26, representing 76% growth compared with the same period a year earlier. EBITDA rose 31% to US$252 million.

Looking ahead, management expects FY26 revenue between US$1.39 billion and US$1.44 billion, with EBITDA forecast between US$550 million and US$585 million.

Another encouraging signal is insider buying.

Recent disclosures show several directors purchasing shares on market in February, including:

• Andrew Harrison buying 1,000 shares at $48.20

• Raelene Murphy buying 2,054 shares at $48.99

• Christopher Charlton buying 2,500 shares at $49.90

Director buying can often be a positive sign because company insiders are committing their own money.

After such a steep sell-off, WiseTech shares could rebound strongly if growth continues and sentiment improves.

CSL Ltd (ASX: CSL)

The CSL share price is currently down 0.44% to $140.04.

The biotechnology giant has also experienced a difficult run recently, with the stock falling roughly 43% over the past year.

This is unusual for a company that has historically been one of the ASX’s most successful global healthcare businesses.

CSL operates through two major divisions.

CSL Behring develops plasma-based therapies used to treat serious medical conditions such as immune deficiencies and haemophilia.

Meanwhile Seqirus is one of the world’s largest influenza vaccine providers.

Demand for plasma therapies continues to grow globally.

The company also maintains a strong pipeline of new treatments that could support future earnings growth.

Following the recent sell-off, some analysts believe the valuation now looks appealing.

One broker has maintained a ‘buy’ rating with a price target around $235, suggesting significant potential upside from current levels.

Foolish bottom line

Both WiseTech and CSL remain globally competitive businesses despite their recent share price weakness.

If I had $10,000 to invest today, I would consider splitting it evenly between these two companies.

The post Where I’d put $10,000 in Australian stocks right now appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 shares at 52-week lows: Buy, hold, or sell?
• Buy, hold, sell: BHP, CSL, and Woodside shares
• 3 ASX shares tipped to race up to 188% higher
• Should I invest $2,000 in the VAS ETF?
• Should you buy CSL and Pro Medicus shares today?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Dug Technology Ltd (ASX: DUG) plays in a specialised niche of the technology market, providing software and compute as a service (CaaS) products to big players in the oil and gas sector.

Shaw and Partners recently ran the ruler over the company and believes they’re deeply undervalued at the moment.

More on that later. Let’s have a look at the most recent statements from the company.

Strong profit uplift

Dug, in its first-half profit statement to the ASX released in late February, said its total revenue came in at US$40.4 million, up 40%, while normalised EBITDA was up 161% to US$13.6 million.

The company said regarding its results:

DUG achieved record financial results in FY26-H1, characterised by significant revenue growth and margin expansion. These results were underpinned by growth in the Services business and the ramp up of the EPIC contract in Malaysia. Services growth was driven by strong performance in both established and emerging regions, and the continued adoption of MP-FWI Imaging technology. DUG expanded its global multi-client portfolio by launching two new seismic reprocessing projects offshore Equatorial Guinea in partnership with Geoex MCG. Both projects are fully pre-funded by clients and cover extensive acreage in the highly prospective deep-water Douala and Rio Muni basins, ahead of upcoming exploration licensing rounds by the Ministry of Hydrocarbons and Mining Development.

Dug Managing Director Dr Matthew Lamont said the company entered the second half “with a high degree of confidence in our growth momentum”.

Shares looking cheap

Shaw and Partners said in a recent research note sent to its clients that Dug had sunk nearly $60 million into high-performance computing infrastructure over the past three years, which it could now leverage for outsized gains.

Shaw and Partners added:

New regions and a growing reputation support contract awards continuing to grow. Dug is favourably exposed to a rising oil price environment, has limited direct revenue exposure to the Middle East currently and has materially underperformed its oil and gas service peers … year to date, creating an opportunity for savvy investors.

Shaw said Dug has only recently expanded into the Middle East, with the region accounting for less than 8% of total revenue.

This was despite the Middle East and Latin America accounting for about 22% of global upstream capex in the sector.

Shaw said Dug was also demonstrating an ability to grow its “share of wallet” with existing customers.

Shaw and Partners has a price target of $3 on Dug shares compared with $2.01 currently.

Dug was valued at $273.7 million at the close of trade on Monday.

The post This ASX 200 technology company is about 50% undervalued, the team at Shaw and Partners says appeared first on The Motley Fool Australia.

More reading

• How does Bell Potter rate these ASX healthcare stocks
• Nvidia CEO reveals massive US$1 trillion AI chip opportunity
• Why are EOS shares crashing 25% today?
• Where I’d put $10,000 in Australian stocks right now
• Which ASX mining project developer is 60% undervalued according to Canaccord Genuity?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Dug Technology. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Centaurus Metals Ltd (ASX: CTM) recently reported some good news, with global mining giant Glencore agreeing to a supply agreement for nickel concentrate from the company’s Jaguar project in Brazil.

The analyst team at Canaccord Genuity subsequently ran the ruler over the company and upgraded its share price for it, which we’ll get to shortly.

Firstly, let’s look in more detail at what the company has reported.

Major milestone achieved

Centaurus said in a statement to the ASX on Monday that it had signed a binding offtake agreement with Glencore, “marking a key step in advancing the project towards development”.

The company added:

The Agreement is for the supply of 20,000 dry metric tonnes per annum of high-grade (32%) nickel concentrate (6,400 tonnes per annum of nickel in concentrate) to Glencore, with the base destination of Canada for treatment at Glencore’s Sudbury smelting operations, and commencing from the beginning of 2029 for a period of five years. The Offtake Agreement with Glencore represents approximately 30% of the planned annual production from Jaguar, with Centaurus retaining flexibility over how the balance its production will be used to support the funding of the Jaguar Project in advance of a Final Investment Decision (FID).  

Pricing under the offtake agreement would be linked to the price of nickel on the London Metals Exchange, the company said, and there would also be credits paid for any copper and cobalt byproducts in the concentrate.

The agreement is subject to the Centaurus board making an FID by 30 September this year and first concentrate production being achieved by 15 January 2029.

The estimated value of the agreement is more than US$450 million over the initial five-year contract term.

Centaurus Managing Director Darren Gordon said it was a milestone for the company.

The signing of our first binding offtake agreement for nickel concentrate production with Glencore is a significant achievement for Centaurus and the Jaguar Nickel Project. Glencore is one of the biggest names in natural resources globally and one of the longest-standing integrated participants in the nickel sector. Signing them up as a long-term offtake partner is a major coup that validates the quality of the Jaguar Project and supports our commercial development strategy. We look forward to building a sustainable low-cost supply of low carbon nickel in Brazil supported by Glencore’s long history in the sector and their deep knowledge of the market. Importantly, the Offtake Agreement will support and help de-risk the ongoing debt and equity funding processes which we currently have underway.

Centaurus shares looking cheap

The team at Canaccord Genuity said they believed the agreement was “a significant step toward the project’s commercial development”.

Canaccord has raised its price target on Centaurus shares to 85 cents, up from 80 cents, compared with the current share price of 53 cents.

If achieved, this would constitute a 60.3% increase. Centaurus was valued at $288.2 million at the close of trade on Monday.

The post Which ASX mining project developer is 60% undervalued according to Canaccord Genuity? appeared first on The Motley Fool Australia.

More reading

• How does Bell Potter rate these ASX healthcare stocks
• Nvidia CEO reveals massive US$1 trillion AI chip opportunity
• Why are EOS shares crashing 25% today?
• Where I’d put $10,000 in Australian stocks right now
• This ASX 200 technology company is about 50% undervalued, the team at Shaw and Partners says

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are 0.32% higher as the market reacts positively to an 0.25% rise in interest rates.

Meanwhile, several ASX 200 stocks hit new 52-week lows today.

Do they present a buying opportunity, or is it best to be cautious on these stocks?

Let’s defer to the experts.

ASX 200 shares at new annual lows today

CSL Ltd (ASX: CSL)

The CSL share price fell to a 52-week low of $138.73 on Tuesday, and is down 43% over 12 months.

Michael Gable from Fairmont Equities has a sell rating on the market’s largest ASX 200 healthcare share.

On The Bull this month, Gable lamented:

This biotechnology giant was a market darling for a long time, but it’s now failing to command a premium as uncertainty surrounding the company’s US vaccine business is making it more difficult for investors to forecast future earnings.

The recent departure of its chief executive also adds to the uncertainty.

From a technical perspective, the stock has topped out and is trending lower.

In my view, this leaves further downside risk in the share price until investors feel more confident that CSL can lift earnings.

Car Group Limited (ASX: CAR)

The Car Group share price fell to a 52-week low of $23.52 on Tuesday.

This ASX 200 communications share has fallen 29% over the past 12 months.

On The Bull this week, Toby Grimm from Baker Young revealed a buy rating on Car Group shares.

He reckons the stock has been caught up in the fear around artificial intelligence (AI) disrupting certain industries.

Grimm commented:

Recent sector-wide selling driven largely by concerns around potential artificial intelligence (AI) disruption has weighed on valuations.

However, we believe CAR’s trusted brands, established distribution network and strong dealer relationships position it well to integrate AI tools into its services rather than be disrupted by them.

Over time, AI could enhance listing quality, pricing transparency and advertising effectiveness across its platforms.

Grimm said the carsales.com.au portal owner produced better-than-expected results for 1H FY26.

They included a 13% lift in revenue and an 11% rise in reported earnings before interest, taxes, depreciation, and amortisation (EBITDA).

He said:

Given the company’s strong market position, attractive margins and long runway for digital automotive marketplace growth across several geographies, we view recent price weakness as an opportunity to accumulate a high quality technology-enabled marketplace at a more reasonable valuation.

Seek Ltd (ASX: SEK)

This fellow ASX 200 communications share tumbled to a 52-week low of $14.42 today.

The Seek share price has fallen 37% over 12 months.

Morgans sees an opportunity at this price level.

After reviewing Seek’s 1H FY26 report, Morgans upgraded the ASX 200 communications share to a buy rating.

Morgans said:

SEK’s 1H26 result was largely as per expectations with net revenue (+12% on pcp), Adjusted EBITDA (+19% on pcp) and adjusted NPAT (+35% on pcp) all broadly in line with Visible Alpha consensus and MorgansF.

Morgans kept its 12-month share price target at $27.50 for Seek shares.

The post 3 ASX 200 shares at 52-week lows: Buy, hold, or sell? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: BHP, CSL, and Woodside shares
• Why this beaten down $9 billion ASX 200 share is now a buy
• Should I invest $2,000 in the VAS ETF?
• 5 things to watch on the ASX 200 on Tuesday
• Should you buy CSL and Pro Medicus shares today?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CAR Group Ltd and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX defence stocks are in the spotlight right now as ongoing geopolitical instability worsens and governments hike defence budgets.

Investors are scrambling to get in on the action, too. 

ASX defence stock superstars like Droneshield Ltd (ASX: DRO) and Electro Optic Systems Holdings Ltd (ASX: EOS) have seen their share prices skyrocket over the past 12 months.

Droneshield shares have jumped 293.2% over the past year alone. The counter drone technology company was one of the fastest-growing stocks on the planet last year. 

Meanwhile, EOS has secured several major contract wins recently, and its shares have risen 728% over the same 12-month period. 

The returns are impressive, and investor and analyst sentiment suggest the share prices of these ASX defence stocks could keep climbing higher this year.

But there are some other lesser-known ASX defence shares which could also experience a boom in value this year.

Titomic Ltd (ASX: TTT)

Titomic specialises in metal additive manufacturing (cold spray technology), which has applications in defence (and other markets). The company manufactures, repairs, and upgrades military equipment using advanced materials such as titanium. This can be done while the equipment is active in the field.

The company’s quarterly update, posted in late-January, revealed global expansion plans, new defence contracts, and strong cash reserves of $35.8 million as of 31st December 2025.

Titomic also recently announced plans to relocate its corporate headquarters to the US as part of its strategy to grow its defence and aerospace business. 

At the time of writing, the Titomic share price is up 2.27% to 22 cents. Over the past month, the shares have climbed 7.14%, but they’re still 13.46% lower over the year.

Just yesterday, Bell Potter confirmed its speculative buy rating and 50 cents price target on the ASX defence stock. That implies a 122.22% upside at the time of writing. The broker said it thinks 2027 could be the year that Titomic’s production really starts to kick off. 

Austal Ltd (ASX: ASB)

Austal is an Australian-based global shipbuilding company specialising in the design, construction, and support of defence and commercial vessels.

These include naval vessels, defence surface warfare combatants, and law enforcement patrol boats.

The company also installs and maintains vessel command and control systems, communication and radar technology, and information management systems.

At the time of writing, Austal shares are down 1.25% for the day to $4.75 each. Over the past month, the shares have fallen 18.49%, but they’re still 24.98% higher than this time 12 months ago.

The company recently cut its earnings guidance for FY26, citing an accounting issue. The news spooked investors and triggered a sell-off.

Most analysts continue to hold a bullish stance on the ASX defence stock. Data shows three out of six analysts have a strong buy rating, two have a hold rating, and one has a strong sell rating.

The average target price is $6.70, which implies a potential 40.96% upside over the next 12 months, at the time of writing. Although some think the shares could jump 61.97% to $7.71 each.

The post These 2 lesser-known ASX defence stocks are tipped to soar appeared first on The Motley Fool Australia.

More reading

• Bell Potter says this ASX defence stock could rocket 130%
• The five worst performing ASX 200 stocks bought and held in February unmasked
• What is Bell Potter’s view on these ASX small-cap stocks?
• These ASX 200 shares sank 20% or more in February
• Austal shares down almost 40% in a month. Is this the bottom?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and Electro Optic Systems and is short shares of DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX Small Ords Index (ASX: XSO) has fallen 10.4% since the war in Iran began, but is 9% higher over the past 12 months.

The S&P/ASX 300 Metal & Mining Index (ASX: XMM) has also dropped 14.4% since the war started, but is up 38% over the past year.

ASX mining shares have been on a tear over the past year as commodity prices have lifted and Australia commenced a new mining boom.

ASX small-caps have also outperformed over the period, largely due to interest rates falling in many Western nations.

The war in Iran may reverse this tailwind, as we’ve seen today with the Reserve Bank of Australia lifting rates again by 0.25%.

As always with small-caps, stock selection is critical.

The following two ASX small-cap mining shares have rocketed over the past 12 months, and these experts say it’s time to sell.

Let’s find out more.

EQ Resources Ltd (ASX: EQR)

The EQ Resources share price is 33 cents, down 9.7% on Tuesday but up 713% over the past year.

EQ Resources owns a tungsten mine in Mt Carbine in North Queensland, and also holds gold exploration licences in NSW.

The company’s long-term ambition is to become Australia’s pre-eminent producer of tungsten, which is used to harden metals.

This month, Morgans issued a new note downgrading this ASX small-cap mining share from a speculative buy rating to a trim rating.

The broker increased its 12-month price target from 16 cents to 23 cents.

Morgans explained the change:

The ammonium paratungstate (APT) price continues to climb, above US$1,600 per metric tonne unit (mtu – 10kg).

We have lifted the modelled short-term price to US$1,300/mtu, and our long-term price from US$600/mtu to US$700/mtu.

With the share price above our target price, we lower our rating to TRIM from Speculative Buy.

Morgans added:

Continued strength in the tungsten price, a most critical metal, could lead to a further increase in our target price.

Lunnon Metals Ltd (ASX: LM8)

The Lunnon Metals share price is 40 cents, down 1.3% today but up 98% over the past 12 months.

Lunnon Metals is a nickel explorer with assets in the Kambalda district of Western Australia.

On The Bull this week, Nathan Lodge from Securities Vault revealed a sell rating on this ASX nickel mining share.

Lodge explained:

The company’s strategy centres on exploring and advancing sulphide nickel deposits in a region historically known for high grade discoveries and established mining infrastructure.

However, global nickel prices have been under sustained pressure as supply from Indonesia has increased rapidly, creating a structural oversupply in the market.

For companies, such as Lunnon Metals, exploration success isn’t sufficient to drive value if the underlying commodity price environment remains weak.

The nickel price is US$17,485 per tonne on Tuesday, up 4% in the year to date and up 7% over the past 12 months.

The post 2 ASX small-cap mining shares to sell: Experts appeared first on The Motley Fool Australia.

More reading

• Why BHP, EQ Resources, Lottery Corp, and Woodside shares are falling today
• This newly-producing ASX gold company could almost double in value: Broker

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.